After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...

The billionaire recently bought an obesity drug stock that could soar nearly 20% over the next 12 months, according to Wall ...

(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

In addition, the decline in overall obesity rate reported by the CDC isn’t the first such drop. Between 1999 and 2018, the ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to ...

David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...

Results from a recent survey have prompted questions about the influence of GLP-1s on the obesity rate of U.S. adults.